Castle will continue its public announcements at the 50th Annual Meeting of the American Society of Clinical Oncology in Chicago, taking place May 30-June 3. At this meeting, two posters will describe the results of two studies evaluating either DecisionDx-EC or another of Castle Bioscience’s bio-marker tests known as DecisionDx-Melanoma.
The biomarker tests were developed in collaboration with University of Texas MD Anderson Cancer Center. They are designed to empower clinicians with diagnostic and prognostic predictions. “The initial clinical goal for our melanoma gene expression profile test was to identify these two out of three patients who are at high risk for metastasis, regardless of sentinel lymph node biopsy eligibility,” explained Derek Maetzold, President and CEO of Castle Biosciences, in material sourced from Castle Biosciences. Sentinel lymph node positivity is currently the standard for detecting high-risk cutaneous melanoma metastasis. Only two of three melanoma patients who metastasize are sentinel lymph node negative, which attenuates the test’s predictive power. Around 76,000 Americans are diagnosed with cutaneous melanoma each year, and 25% show evidence of melanoma spreading beyond the primary tumor.
“At ASCO we will present data that focus on a cohort of patients who received both our gene expression profile test and a sentinel lymph node biopsy and confirm our initial validation study results,” said Maetzold. This poster will be presented on June 2 during the Melanoma/Skin Cancers Session by David H. Lawson, MD, from Winship Cancer Institute at Emory University in Atlanta.
The second poster, which discusses the use of DecisionDx-EC to predict neoadjuvant treatment response for patients with esophageal or rectal adenocarcinoma, will be presented on May 31 by Sunil S. Badve, MD, FRCPath, from Indiana University School of Medicine. Castle Biosciences will also host a booth at the meeting with more information about DecisionDx-Melanoma and DecisionDx-EC, as well as its DecisionDx-Thymoma and DecisionDx-Mesothelioma tests.